NCT02381132TerminatedPhase 3
A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain
Neil Singla1 site in 1 country99 target enrollmentStarted: November 2014Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Terminated
- Sponsor
- Enrollment
- 99
- Locations
- 1
- Primary Endpoint
- Post-operative Pain Control
Study Overview
Brief Summary
The purpose of this study is to explore the clinical characteristics oral MNK155 and Norco® 7.5mg/325mg when used for the treatment of moderate to severe post operative pain.
Detailed Description
This is a single center, open label, prospective, randomized study on adult post operative subjects who are expected to require oral opioid analgesia for at least 48 hours after surgery. The main study drug of interest in this study is MNK 155. Norco® 7.5mg/325mg is being utilized only as active comparator.
Subjects will be at least 18 years of age and will be scheduled to undergo elective surgery. The following surgical types will be allowed, although the list is not all inclusive:
- Abdominal surgery
- Soft tissue surgery
- Orthopedic surgery
- Spine surgery
- Genitourinary surgery
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects who provide written informed consent prior to enrollment.
- •Male or female and 18 years of age or older.
- •Subjects who are scheduled to undergo elective general surgery including, but not limited to the following surgical types:
- •Abdominal surgery
- •Orthopedic surgery
- •Spine surgery
- •Genitourinary surgery
- •Subjects classified as American Society of Anesthesiologists (ASA class I-III).
- •Female subjects are eligible only if all of the following apply:
- •Not pregnant (subjects of child bearing potential must have a negative beta human chorionic gonadotropin (β-hCG) pregnancy test before surgery);
- •Not lactating;
- •Not planning to become pregnant within the duration of the study;
- •Subjects who are expected to have acute pain requiring oral opioid analgesics for at least 48 hours during the post operative period (either inpatient or outpatient).
- •Subjects who are willing and capable of understanding and cooperating with the requirements of the study.
- •Subjects able to understand and communicate in English.
Exclusion Criteria
- •Subjects with a medical condition that, in the Investigator's opinion, could adversely impact the subject's participation, safety, or conduct of the study such as but not limited to a history of severe renal or hepatic impairment, severe active hepatic disease, or any other clinically significant medical condition that may preclude safe study participation.
Arms & Interventions
MNK155
Active Comparator
Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
Intervention: MNK155 (Drug)
Norco 7.5mg/325mg
Active Comparator
Norco 7.5mg/325mg
Intervention: Norco 7.5mg/325 (Drug)
Outcomes
Primary Outcomes
Post-operative Pain Control
Time Frame: 48 hours
Patient Global Assessment
Secondary Outcomes
- Opioid Related Symptoms(48 hours after treatment initiation)
- Subject Reported Worst Pain (Secondary to Analgesic Gaps)(24 hours after treatment initiation)
- Total Daily Acetaminophen Exposure(24 hours, 48 hours, 72 hours, 96 hours and 120 hours after treatment initation)
- Post-operative Pain Control(120 hours)
- Post-operative Pain Control as Assessed by the Healthcare Professional(48 and 120 hours)
- Subject Satisfaction Regarding Ease of Use and Pill Burden(48 hours and 120 hours after treatment initation)
- Sleep Disturbance(24 hours, 48 hours and 72 hours after treatment initiation)
- Pill Diversion(Day 5)
Investigators
Neil Singla
Coordinating Investigator
Lotus Clinical Research, LLC
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsHemophilia a and BNCT06747416Suzhou Alphamab Co., Ltd.24
Completed
Phase 3
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in JapanOveractive BladderNCT00212732Ono Pharmaceutical Co. Ltd750
Completed
Phase 2
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in JapanOveractive BladderNCT00212706Ono Pharmaceutical Co., Ltd.400
Completed
Phase 3
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial PneumoniaPneumoniaNCT01561794Bayer44
Completed
Phase 1
Study of KRN951 in Patients With Solid TumorsSolid TumorsNCT00970411Kyowa Kirin Co., Ltd.12